News
News/ News/ News/ Oncology/ Sales and Marketing
Bayer bags swift OK for Nubeqa in metastatic prostate cancer
Phil Taylor
Bayer, Erleada, Nubeqa, Oncology, Orion, Prostate cancer, regulatory approval, Xtandi
0 Comment
News/ News/ Sales and Marketing
Pfizer bid for sickle cell drug developer GBT said to be imminent
Phil Taylor
Global Blood Therapeutics, M&A, Oxbryta, Pfizer, sickle cell disease
0 Comment
News/ News/ News/ Patients/ Sales and Marketing
Bayer tops pharma rankings for diversity, inclusivity
Phil Taylor
alva, Astellas, Bayer, diversity and inclusion, Eli Lilly, Gilead Sciences, pharma reputation, Sanofi, Teva
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy
Phil Taylor
adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod
Phil Taylor
biosimilar, Byooviz, Cimerli, Coherus, Lucentis, Novartis, Roche, Samsung Bioepis
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
Gilead Sciences’ push into oncology is paying off, as Veklury falters
Phil Taylor
Gilead Sciences, Sales and Marketing, Tecartus, Trodelvy, Veklury, Yescarta
0 Comment
News/ News/ News/ Patients/ Sales and Marketing
US government buys 66m doses of Moderna’s Omicron booster
Phil Taylor
BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Moderna, Omicron, Pfizer, US
0 Comment
News/ News/ Sales and Marketing
AstraZeneca raises 2022 guidance, names Demaré as non-exec chair
Phil Taylor
AstraZeneca, Enhertu, Evusheld, Farxiga, Financial, Oncology, Rare diseases
0 Comment